GW Pharma reveals partner for THC drug
The UK's GW Pharmaceuticals has announced its long-awaited marketing agreement for its cannabis-based painkiller, revealing that Bayer AG has licensed exclusive commercialization rights to the drug in the UK and an option to negotiate for similar deals in the European Union and certain other world markets. GW has also announced that the product, a whole-plant medicinal cannabis extract containing tetranabinex (tetrahydrocannabinol) and nabidiolex (cannabidiol), will be sold under the Sativex trade name.
The firm filed for approval of Sativex in the UK in March as a treatment for the debilitating symptoms of multiple sclerosis and severe neuropathic pain. The medicine is administered by means of a spray into the mouth, and is also being developed in Phase III trials as a treatment for cancer pain.
Financial terms
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze